Haginir 125 DHG nuggets treat infections (24 packs)

Dosage form 24 package box
Specifications Cefdinir

Ingredient

Composition information	Content
Cefdinir	125mg

Uses

indications

Haginir 125mg drug indicated for treatment of mild to medium infections caused by sensitive bacteria:

For children from 6 months to under 13 years: sore throat, tonsillitis, acute sinusitis, acute otitis media, skin infections and uncomplicated skin structure.

Pharmacokology

cefdinir is an antibiotic of the 3rd generation cephalosporin group, which has bactericidal effects due to synthetic inhibition of bacterial cell walls.

Invitro tests and clinical studies show that CEFDinir has a spectrum of high -negative resistance to Gram -negative bacteria such as Haemophilus Influenza, Haemophilus parainfluenzae, Moraxella Catarrhalis (including beta -lactamase secretion) and Gram -positive bacteria such as Staphylococcus Aureus (including Beta -Tieu Beta. lactamase), Streptococcus pneumoniae (strain sensitive to penicillin), Streptococcus pyogenes.In addition, Invitro results also show that CEFDinir has an effective resistance to some other gram -negative bacteria such as Citrobacter Diversus, Escherichia Coli, Klebsiella Pneumoniae, Proteus Mirabili and Gram Yang such as Staphylococcus Epidermidis (Methiciline sensitive strain) Agalactiae, Streptococci group Viridans.

Cefdinir is not affected by some types of beta - lactamase enzymes, especially good effect on Gram -positive bacteria such as Staphylococcus sp., Streptococcus sp., resistant to antibiotics of other oral cephalosporin groups before. Enterococci strains (Enterococcus Faecalis), Pseudomonas, Enerobacter and Staphylococci resistant methicilin are resistant to cefdinir.

Bacterial resistance mechanism of bacteria is to reduce Cefdinir's affinity for target protein or reduce the permeability of bacterial cell membranes for drugs.

Cefdinir is highly sustainable with the hydrolysis of beta-lactamase encoded by gene on plasmid and chromosom.

Cefdinir is stable before some beta-lactamase enzymes, but not all, so the Cefdinir resistance mechanism has a cup due to some beta-lactamase.

Dynamic pharmacokinetics

After taking Cefdinir, the peak of plasma peaks reached 2-4 hours. Absolute bioavailability is about 25 % when used in the form of oral fluid.

Cefdinir is distributed into the middle ear fluid, tonsils, sinus tissue, bronchial, pulmonary mucosa, ... at different concentrations in plasma.

In patients with acute otitis media caused by bacteria when taking the dose of 7 mg or 14 mg/ kg, the average concentration of the drug in the middle ear epidemic is 3 hours after taken.

The average distribution of CEFDinir in adults is 0.35 l/ kg (± 0.29); In children from 6 months old to 12 years old is 0.67 l/ kg (± 0.38).

CEFDINIR's cohesion ratio is 60 - 70%, this cohesion is independent of the concentration of the drug.

In patients from 6 months to 12 years old, taking a single dose of 7 mg/ kg Cefdinir in the form of a chaos, the top concentration of plasma is at 2.2 hours after use.

When used in a single dose of 14 mg/ kg for these patients, the peak concentration of plasma is 1.8 hours after drinking.

Concomitance CEFDinir is oral with a high -fat meal that reduces the peak concentration in plasma and AUC of the drug, equivalent to 44% and 33%.

There is no evidence that CEFDinir accumulates in plasma after taking multiple doses in patients with normal kidney function at a dose of 2 times/ day.

Cefdinir metabolizes negligible. The drug is excreted mainly in the kidneys. In adults with normal kidney function, the average selling time in plasma of Cefdinir is 1.7 - 1.8 hours.

CEFDINIR's clearance in patients with impaired renal function. In patients with creatinine clearance of 30 - 60 ml/ min, peak plasma concentrations and half -blood semi -discharged time increased by 2 times and AUC tripled.

In patients with creatinine clearance below 30 ml/ min, the peak concentration in plasma increased by 2 times but the half -life of plasma and AUC increased by 5-6 times respectively. Cefdinir is removed from the body through the hemorrhage.

About 63% of the drug is removed from the body for 4 hours according to the fertilizer line. CEFDINIR's waste sale time in patients with severe renal failure decreases from 16 to 3.2 hours.

Before taking Haginir 125 DHG nuggets treat infections (24 packs)

How to use

Haginir 125mg oral medicine.

Mixed with sufficient water (about 5 - 10 ml of water for 1 pack), stir before drinking.

Dosage

The total daily dose for bacterial infections is 14 mg/ kg body weight/ day (maximum 600 mg/ day).

Children from 6 months to under 13 years old:

Sore throat, tonsillitis: 7 mg/ kg body weight 2 times/ day, for 5-10 days. Or 14 mg/ kg body weight/ day, for 10 days. Or 14 mg/ kg body weight/ day, for 10 days. Or 14 mg/ kg body weight/ day, for 10 days.

Children aged 13 years or older or over 43 kg and adults recommend using the form of dosage in accordance with the following dose:

Sore throat and tonsillitis: 300 mg x 2 times/ day, for 5-10 days. Or 600 mg x 1 time/ day, for 10 days. Or 600 mg x 1 time/ day, for 10 days. Or 600 mg x 1 time/ day, for 10 days.

Community pneumonia: 300 mg x 2 times/ day, for 10 days.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Overdose treatment is mainly symptomatic treatment and drugs from the body. Hematopathy can be carried out to prevent the drug from the blood.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

There are 2289 patients with children (including 1783 patients in the US and 506 patients in other countries) were treated with CEFDinir in the recommended dose of 14 mg/ kg/ day. There is no death or permanent disability related to Cefdinir. 40/2289 (2%) Patients who stop the drug due to unwanted effects according to the research of the researcher is related to CEFDinir.

Stop medication is mainly due to digestive disorders, usually diarrhea, 5/2289 (0.3%) of patients stopping the drug due to the rash that is considered to be related to Cefdinir.

The following unwanted effects are reported on 1783 patients using Cefdinir in clinical trials in the US:

Bacterial infections: Skin candidiasis, vulva - vaginal candidia, vaginal infection. Patches.

Changing the following testing values may be clinically significant, which has been observed in clinical trials, whether related to Cefdinir therapy. The following changes have a greater ratio or 1%.

Examination: leukemia, leukemia, hyper enzyme alkaline phosphatase blood, hypoglycemia, hyperphaulocytic eosine, hyper enzyme lactate dehydrogenase in blood, platelet hyperglycemia, neutrophils, neutrophils, protein urine.

In addition to the unwanted effects reported in clinical trials, changing test indicators, there are reports in use experience, started approved in Japan in 1991 including:

Bacterial infection: fake colitis, pneumonia Man. The feeling of suffocation. Type, dermatitis, nodules, sensitive vasculitis. Inform the doctor the unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Haginir 125mg drug contraindicated in the following cases:

Hypersensitivity to cephalosporin or any ingredients of the drug.

Be cautious when using

Before starting treatment with cefdinir, a thorough investigation of the patient's allergic history with cephalosporin, penicilin or other drugs.

Using long -term drugs can lead to superinfection of bacteria and fungi; Especially, Clostridium Difficile is infected with diarrhea and colitis.

Use the drug until the end of the treatment, even though the symptoms are no longer after a few days of treatment. The stop use of the drug too early can continue to grow, resulting in infection recurrence and will not be able to be treated with CEFDinir or other antibiotics.

Caution for patients with renal failure.

Safety and effectiveness of Cefdinir in children under 6 months of age has not been confirmed.

Women during pregnancy and lactation

The effect on pregnant women: Experimental animal studies show that CEFDinir is relatively safe when used during pregnancy, but there is no adequate and well -controlled research on pregnant women, only use drugs when really necessary.

Breastfeeding period: After using a single dose of 600 mg, Cefdinir is not detected in breast milk. Be cautious when using Cefdinir during breastfeeding.

The ability to drive and operate machinery

cefdinir can cause headaches, dizziness, need to be cautious when driving and operating machinery.

Drug interaction

should take at least 2 hours after taking antacids or iron preparations because of reducing bioavailability.

Probenecid inhibits cefdinir excretion.

Affects subclinical results: The false positive result can occur when finding a way in urine with Benedict's solution, Fehling and Clinitest solutions. The direct positive coombs reaction may occur.

Storage

In a dry place, the temperature does not exceed 30 ° C, avoiding light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.